Related Experiment Videos
Mid-term experience with valved bovine jugular vein conduits
Malgorzata Pawelec-Wojtalik1, Wojciech Mrówczyński, Andrzej Wodziński
1, Department of Pediatric Cardiac Surgery, Poznan University of Medical Sciences, 27/33 Szpitalna, Poznan 60-572, Poland. wjmrow@amp.edu.pl.
Asian Cardiovascular & Thoracic Annals
|November 24, 2005
Summary
Valved bovine jugular vein conduits offer a viable alternative for complex congenital heart defect repair in children, showing good long-term outcomes despite some complications.
Area of Science:
- Pediatric Cardiology
- Cardiovascular Surgery
- Biomaterials in Medicine
Background:
- Complex congenital heart defects often require surgical intervention.
- Valved conduits are crucial for correcting these defects, particularly in the right ventricular outflow tract.
- Bovine jugular vein conduits represent an alternative to traditional homografts.
Purpose of the Study:
- To evaluate the efficacy and safety of valved bovine jugular vein conduits in pediatric patients with complex congenital heart defects.
- To assess conduit performance, long-term survival, and complication rates.
Main Methods:
- Retrospective analysis of 43 pediatric patients undergoing implantation of valved bovine jugular vein conduits.
- Assessment of early and late mortality, conduit-related complications, re-interventions, and hemodynamic parameters.
- Follow-up duration ranged from 1 to 48 months.
Main Results:
- Seven early deaths (16.3%) occurred, unrelated to conduit failure.
- Three late deaths (8.3%) were attributed to infection, pulmonary thromboembolism, and re-operation complications.
- Freedom from re-intervention was 72% at 48 months, with no severe valve regurgitation.
- Mean peak gradient across the pulmonary anastomosis was 15 mm Hg in re-intervention-free patients.
Conclusions:
- Valved bovine jugular vein conduits are a suitable alternative to homografts for complex congenital heart defect repair in children.
- Further research is needed to address distal stenosis, establish anticoagulation guidelines, and define the role of percutaneous balloon dilatation.